Viatris Inc. VTRS
17.83
0.41
2.35%
as of 25 Sep
- Market cap
- $20.0B
- P/E
- 0.0×
Follow VTRS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Viatris Inc. (VTRS) Shares outstanding
Viatris Inc.'s shares outstanding at the end of fiscal 2025 was $1.2B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $1.2B. Over the past ten years it has ranged from $497.4M (fiscal 2015) to $1.2B (fiscal 2022); the current reading is higher than 64% of that period. Viatris Inc. ranks 4th of 83 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Annual
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $1.2B | (1.89%) |
| FY2024 | $1.2B | (1.13%) |
| FY2023 | $1.2B | (0.86%) |
| FY2022 | $1.2B | 0.71% |
| FY2021 | $1.2B | 101.06% |
| FY2020 | $601.2M | 16.40% |
| FY2019 | $516.5M | 0.00% |
| FY2018 | $516.5M | (3.76%) |
| FY2017 | $536.7M | 3.11% |
| FY2016 | $520.5M | 4.64% |
Quarterly
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $1.2B | (1.02%) |
| Mar 2026 | $1.2B | 0.39% |
| Dec 2025 | $1.2B | 0.52% |
| Sep 2025 | $1.2B | (0.72%) |
| 42 more quarters | Free account |
Against its own ten years
Low $497.4M
High $1.2B
Ten-year median
$601.2M
Current reading's percentile
64
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $4.6B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.2B |
| VTRS Viatris Inc. | $1.2B |
| RDY Dr. Reddy's Laboratories Ltd compare | $783.3M |
| ELAN Elanco Animal Health Incorporated compare | $505.9M |
| ZTS Zoetis Inc. compare | $417.7M |
| HIMS Hims & Hers Health, Inc. compare | $231.7M |
| NBIX Neurocrine Biosciences, Inc. compare | $104.2M |
| UTHR United Therapeutics Corporation compare | $45.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on VTRS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- The full statement